Literature DB >> 1320670

Immunoreactivity for the beta chain of the platelet-derived growth factor receptor in malignant mesothelioma and non-neoplastic mesothelium.

M Ramael1, C Buysse, J van den Bossche, K Segers, E van Marck.   

Abstract

The results of an immunohistochemical study of platelet-derived growth factor receptor (PDGF-R) beta chain in human non-neoplastic mesothelium (35 cases) and in malignant mesothelioma (33 cases) using a murine monoclonal antibody are reported. In approximately half of the malignant mesotheliomas, there was immunoreactivity in the cytoplasm of the neoplastic cells for the beta chain of the PDGF-R. In some cases, there was also membrane immunoreactivity. There were no statistically significant differences between the various mesothelioma subtypes. Immunoreactivity for PDGF-R beta chain was absent in non-neoplastic mesothelium.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1320670     DOI： 10.1002/path.1711670102

Source DB:  PubMed          Journal:  J Pathol        ISSN： 0022-3417            Impact factor:   7.996


  8 in total

Review 1.  Malignant mesothelioma: new insights into tumour biology and immunology as a basis for new treatment approaches.

Authors:  J W Upham; M J Garlepp; A W Musk; B W Robinson
Journal:  Thorax       Date:  1995-08       Impact factor: 9.139

2.  Immunoreactivity for bcl-2 protein in malignant mesothelioma and non-neoplastic mesothelium.

Authors:  K Segers; M Ramael; S K Singh; J Weyler; J Van Meerbeeck; P Vermeire; E Van Marck
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

Review 3.  Overexpressed genes in malignant pleural mesothelioma: implications in clinical management.

Authors:  Elisa Barone; Federica Gemignani; Stefano Landi
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

4.  Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma.

Authors:  Anne S Tsao; Nusrat Harun; Junya Fujimoto; Vikki Devito; J Jack Lee; Elisabetta Kuhn; Reza Mehran; David Rice; Cesar Moran; Waun Ki Hong; Li Shen; Milind Suraokar; Ignacio Wistuba
Journal:  Ann Diagn Pathol       Date:  2014-02-20       Impact factor: 2.090

5.  FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma.

Authors:  Catherine T-S Chung; Gilda Da Cunha Santos; David M Hwang; Olga Ludkovski; Melania Pintilie; Jeremy A Squire; Ming-Sound Tsao
Journal:  J Clin Pathol       Date:  2010-07       Impact factor: 3.411

6.  Expression of cancer-associated molecules in malignant mesothelioma.

Authors:  Ben Davidson
Journal:  Biomark Insights       Date:  2007-05-30

7.  Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines.

Authors:  Ombretta Melaiu; Calogerina Catalano; Chiara De Santi; Monica Cipollini; Gisella Figlioli; Lucia Pellè; Elisa Barone; Monica Evangelista; Alice Guazzelli; Laura Boldrini; Elisa Sensi; Alessandra Bonotti; Rudy Foddis; Alfonso Cristaudo; Luciano Mutti; Gabriella Fontanini; Federica Gemignani; Stefano Landi
Journal:  Genes Cancer       Date:  2017-01

8.  High tumor cell platelet-derived growth factor receptor beta expression is associated with shorter survival in malignant pleural epithelioid mesothelioma.

Authors:  Hely Ollila; Juuso Paajanen; Henrik Wolff; Ilkka Ilonen; Eva Sutinen; Katja Välimäki; Arne Östman; Sisko Anttila; Eeva Kettunen; Jari Räsänen; Olli Kallioniemi; Marjukka Myllärniemi; Mikko I Mäyränpää; Teijo Pellinen
Journal:  J Pathol Clin Res       Date:  2021-05-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.